Research Alert
BACKGROUND
News — As living biodrugs, mesenchymal stem cells (MSCs) have progressed to phase 3 clinical trials for cardiovascular applications. However, their limited immediate availability hampers their routine clinical use.
AIM
To validate our hypothesis that cryopreserved MSCs (CryoMSCs) are as safe and effective as freshly cultured MSC counterparts but carry logistical advantages.
METHODS
Four databases were systematically reviewed for relevant randomized controlled trials (RCTs) evaluating the safety and efficacy of CryoMSCs from various tissue sources in treating patients with heart disease. A subgroup analysis was performed based on MSC source and post-thaw cell viability to determine treatment effects across different CryoMSCs sources and viability status. Weighted mean differences (WMDs) and odds ratios were calculated to measure changes in the estimated treatment effects. All statistical analyses were performed using RevMan version 5.4.1 software.
RESULTS
Seven RCTs (285 patients) met the eligibility criteria for inclusion in the meta-analysis. During short-term follow-up, CryoMSCs demonstrated a significant 2.11% improvement in left ventricular ejection fraction (LVEF) [WMD (95%CI) = 2.11 (0.66-3.56), P = 0.004, I2 = 1%], with umbilical cord-derived MSCs being the most effective cell type. However, the significant effect on LVEF was not sustained over the 12 months of follow-up. Subgroup analysis demonstrated a substantial 3.44% improvement in LVEF [WMD (95%CI) = 3.44 (1.46-5.43), P = 0.0007, I2 = 0%] when using MSCs with post-thaw viability exceeding 80%. There was no statistically significant difference in the frequency of major cardiac adverse events observed in rehospitalization or mortality in patients treated with CryoMSCs vs the control group.
CONCLUSION
CryoMSCs are a promising option for heart failure patients, particularly considering the current treatment options for cardiovascular diseases. Our data suggest that CryoMSCs could be a viable alternative or complementary treatment to the current options, potentially improving patient outcomes.
Key Words: ; ; ; ; ; ;
Core Tip: Our study yields significant findings that are crucial for regenerative medicine and cardiology. Our findings revealed that cryopreserved mesenchymal stem cells (CryoMSCs) treatment, compared to the control group, resulted in a 2.11% improvement in left ventricular ejection fraction during six months of follow-up, offering hope for potential future therapies. Left ventricular ejection fraction improvement was higher when using umbilical cord-derived mesenchymal stem cells or CryoMSCs with more than 80% post-thaw viability. The CryoMSCs treatment was safe, as there was no significant difference in the incidence of major cardiac adverse events compared to the control group. In addition, no significant effects on mortality and readmission were observed in the CryoMSCs group compared to the control group.
- Citation: Safwan M, Bourgleh MS, Haider KH. Clinical experience with cryopreserved mesenchymal stem cells for cardiovascular applications: A systematic review. World J Stem Cells 2025; 17(3): 102067
- URL:
- DOI:
RSS